Poractant alfa versus bovine lipid extract surfactant: prospective comparative effectiveness study Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • OBJECTIVE: To compare short term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa. STUDY DESIGN: Prospective comparative effectiveness cohort study of infants <32 weeks' gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support. RESULT: 968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission. CONCLUSION: In this pragmatic study, we did not identify any difference in short term outcomes between the groups based on the type of surfactant received.

authors

  • Lemyre, Brigitte
  • Lacaze-Masmonteil, Thierry
  • Shah, Prakesh S
  • Bodani, Jaya
  • Doucette, Stefanie
  • Dunn, Michael
  • Louis, Deepak
  • Monterrosa, Luis
  • Mukerji, Amit
  • Schmölzer, Georg M
  • Singh, Balpreet
  • Wong, Jonathan
  • Ye, Xiang Y
  • Offringa, Martin

publication date

  • April 2022